« A disruptive technology, which can be applied in the treatment of numerous conditions »

Theranexus publishes its cash position as of 30 June 2024 and presents an update on the progress of Batten-1

11/07/2024 18:30

Télécharger le PDF (<1Mo)

THERANEXUS, LYON NEUROSCIENCE RESEARCH CENTER AND CERMEP WIN THE “2024 RESEARCH PACT” PROJECT FOR THE AUVERGNE-RHÔNE-ALPES REGION

03/07/2024 7:30

Télécharger le PDF (<1Mo)

Theranexus, Diverchim and Inserm awarded €4.7 million in funding under the “Innovations in biotherapies and biomanufacturing” call for proposals from France 2030 to develop a novel antisense oligonucleotide

23/04/2024 07h30
Télécharger le PDF (<1Mo)

Theranexus publishes its 2023 full year results and presents its progress report

29/04/2024 18:00

Télécharger le PDF (<1Mo)

Theranexus and BBDF announce final and positive safety and efficacy data in the Phase I/II trial testing Batten-1

18/04/2024 18h00
Télécharger le PDF (<1Mo)

Theranexus announces appointment of Mathieu Charvériat as Board of Directors Chairman 

11/03/2024 8am CET
Download PDF File (<1 Mo)

Theranexus publishes its cash position as of December 31st 2023 and presents an update on its programs 

14/02/2024
Download PDF File (<1 Mo)